1-3 of 3
Michael Kadan
Close
Sort by
Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Paolo F. Caimi, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Julie K Ritchey, Tabatha Trummer, Jennifer Schiavone, Kayla Zamborsky, Linda G Eissenberg, Julia Hollaway, Dina Schneider, Kristen Bakalarz, Kirsten M Boughan, Leland Metheny, III, Seema Patel, Erin Galloway, Molly Gallogly, Winfried Krueger, Michael Kadan, Gabriela Pacheco Sanchez, Ashish Sharma, David Wald, Brenda W. Cooper, John F. DiPersio, Rafick Sekaly, Rimas J Orentas, Boro Dropulic, Marcos J.G. de Lima
Journal: Blood
Blood (2021) 138 (Supplement 1): 3833.
https://doi.org/10.1182/blood-2021-151155
Published: 2021
Journal Articles

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Paolo F Caimi, MD, Ashish Sharma, Patricio Rojas, MD, Seema Patel, PharmD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Andrew Worden, Michael Kadan, Michael Maschan, MD PhD, Rimas J Orentas, PhD, Boro Dropulic, PhDMBA, Rafick Sekaly, Marcos de Lima, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-143114
Published: 2020
Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Paolo F Caimi, MD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Dina Schneider, PhD, Kristen Bakalarz, CNP, Kirsten M Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MD PhD, Erin Galloway, RN BSN, Winfried Kruger, Andrew Worden, Michael Kadan, Filipa Blasco Lopes, Ashish Sharma, Ehsan Malek, MD, Leland Metheny, III, MD, Seema Patel, PharmD, Benjamin K. Tomlinson, MD, David Wald, MD PhD, Rafick-Pierre Sekaly, Rimas Orentas, PhD, Boro Dropulic, PhD, Marcos de Lima, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4074.
https://doi.org/10.1182/blood-2019-131300
Published: 2019